聯邦制藥(03933.HK)上半年純利6.23億元 同比上升207.2%
格隆匯8月27日丨聯邦制藥(03933.HK)發佈公吿，截至2021年6月30日止6個月，實現收益人民幣47.19億元，同比上升9.6%；毛利20.96億元，同比上升16.57%；公司股東應占溢利人民幣6.23億元，同比上升207.2%；基本每股盈利人民幣33.86分；擬派中期息每股人民幣4分。
2021年上半年，集團各項生產及營運工作平穩推進，繼續為全球範圍內抗擊疫情、維護藥品供應鏈穩定貢獻積極力量。期內，中間體、原料藥及製劑產品的分部營業額分別約為人民幣8.22億元、人民幣19.68億元及人民幣19.29億元，較去年同期分別上升18.9%、5.7%及10.2%。期內，中間體、原料藥及製劑產品的分部溢利分別約為人民幣2.18億元、人民幣1.41億元及人民幣4.81億元，較去年同期分別上升135.9%、下降15.3%及上升15.2%。
在行業加速整合的趨勢下，擁有核心戰略品種、潛力的在研管線及高素質的人才團隊將助力企業在市場競爭中脱穎而出。未來，集團將繼續聚焦及重點佈局糖尿病領域，積極拓展市場覆蓋，加強品牌推廣與專業服務，不斷提升綜合競爭力，提升集團於內分泌及其他專科領域的市場地位。在醫藥政策不斷變革的背景下，創新是企業可持續發展的生命力來源。集團將繼續加強針對新藥研發的資源投放，拓展治療領域、開發具備市場潛力的創新產品，以滿足中國市場的醫療需求。此外，鞏固及拓展科研團隊，提升科研綜合實力，積極迎接以研發創新所帶動的企業轉型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
